- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
- Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
- Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
- Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
- Cerus Corporation to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Thursday, Cerus Corp (CERS:NMQ) closed at 1.89, 56.85% above the 52 week low of 1.21 set on Oct 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.81 |
---|---|
High | 1.91 |
Low | 1.79 |
Bid | 1.83 |
Offer | 1.92 |
Previous close | 1.79 |
Average volume | 3.59m |
---|---|
Shares outstanding | 181.28m |
Free float | 174.46m |
P/E (TTM) | -- |
Market cap | 324.50m USD |
EPS (TTM) | -0.2086 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼